NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 4,910 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 4,910 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60. Following the transaction, the insider now directly owns 5,540,104 shares in the company, valued at $36,897,092.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total transaction of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Stock Up 1.3 %

NPCE opened at $6.47 on Friday. NeuroPace, Inc. has a fifty-two week low of $5.73 and a fifty-two week high of $18.15. The company has a market capitalization of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78. The company has a debt-to-equity ratio of 5.97, a current ratio of 6.37 and a quick ratio of 5.47. The firm’s fifty day moving average price is $7.05 and its two-hundred day moving average price is $8.41.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. The firm had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.36) earnings per share. On average, analysts anticipate that NeuroPace, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on NPCE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research report on Wednesday, August 14th. Wells Fargo & Company lowered their target price on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Finally, Morgan Stanley dropped their price target on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Hedge Funds Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in NeuroPace by 18.3% during the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after acquiring an additional 75,512 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of NeuroPace in the 1st quarter worth about $155,000. Millennium Management LLC grew its holdings in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of NeuroPace during the 1st quarter worth about $621,000. Finally, Financial Advocates Investment Management lifted its holdings in NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.